VEGFC and neoplasm: A recent study has shown that inhibition of NRP2 disrupts vascular endothelial growth factor C-induced lymphatic endothelial cell migration, reduces tumor lymphangiogenesis, and inhibits metastasis to sentinel lymph nodes and distant organs by delaying the departure of tumor cells from the primary tumor [81].